Suppr超能文献

在接受适形放疗的乳腺癌患者中,我们是否应将甲状腺视为危险器官?单中心剂量学研究。

Should we consider thyroid gland as an organ at risk in carcinoma breast patients receiving adjuvant radiation by conformal technique? A single institute dosimetric study.

机构信息

Department of Radiation Oncology, Mehdi Nawaz Jung Institute of Oncology and Regional Cancer Centre, Hyderabad, Telangana, India.

Department of Medical Physics, Mehdi Nawaz Jung Institute of Oncology and Regional Cancer Centre, Hyderabad, Telangana, India.

出版信息

Indian J Cancer. 2020 Oct-Dec;57(4):393-397. doi: 10.4103/ijc.IJC_607_18.

Abstract

BACKGROUND

The most common malignancy among Indian women is carcinoma of the breast. In the management of breast cancer (BC), radiation therapy (RT) is given to breast or chest wall and supraclavicular lymph nodal (SCLN) area, with at least part of the thyroid receiving RT dose.There is an increased incidence of hypothyroidism (HT) among BC patients after RT involving the SCLN area. Moreover, the incidence of HT in India is higher than in the West. The aim of our study is to dosimetrically evaluate the thyroid doses during RT for BC.

METHODS

This is a single institute prospective study (n = 131). Radiation was planned by three-dimensional conformal radiation therapy (3D-CRT) technique and dose-volume parameters for thyroid gland were noted.

RESULTS

The median thyroid gland volume was 7.4 cc. The median of the mean dose to thyroid gland was 2068 cGy, V10 was 42%, and V40 was 33%. In other studies, BC patients with smaller thyroid gland were more prone to HT (volume <8 cc). In our study, we have seen that the median thyroid volume was 7.4 cc.

CONCLUSION

Our study showed a lower mean dose to the thyroid gland and smaller volume thyroid glands than in the literature. As the incidence of HT is higher in India, compared to the west and our patients had small volume thyroid glands, they could be at higher risk of developing HT RT. So BC patients should be monitored for HT and should be given a dose constraint while planning RT.

摘要

背景

印度女性最常见的恶性肿瘤是乳腺癌。在乳腺癌(BC)的治疗中,放射治疗(RT)会应用于乳房或胸壁和锁骨上区域的淋巴结(SCLN),至少部分甲状腺会接受 RT 剂量。在包括 SCLN 区域在内的 RT 后,BC 患者中甲状腺功能减退症(HT)的发病率增加。此外,印度的 HT 发病率高于西方。我们的研究旨在对涉及 SCLN 区域的 BC 患者的 RT 期间的甲状腺剂量进行剂量学评估。

方法

这是一项单机构前瞻性研究(n=131)。通过三维适形放射治疗(3D-CRT)技术进行放射治疗计划,并记录甲状腺的剂量-体积参数。

结果

甲状腺腺体的中位数体积为 7.4cc。甲状腺平均剂量的中位数为 2068cGy,V10 为 42%,V40 为 33%。在其他研究中,甲状腺较小的 BC 患者更易发生 HT(体积<8cc)。在我们的研究中,我们发现中位数甲状腺体积为 7.4cc。

结论

我们的研究显示,甲状腺的平均剂量和较小的甲状腺体积均低于文献中的数据。由于印度的 HT 发病率高于西方,并且我们的患者甲状腺体积较小,他们可能面临更高的 HT RT 风险。因此,在计划 RT 时,BC 患者应监测 HT,并给予剂量限制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验